Wedbush Securities’s Zevra Therapeutics ZVRA Stock Holding History

Wedbush Securities’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,747	Closed	-$47K	–	1023
2019 Q4	$47K	Buy	7,747 +1,658	+27%	+$13.2K	﹤0.01%	966
2019 Q3	$67K	Buy	6,089 +5,363	+739%	+$96.9K	0.01%	919
2019 Q2	$20K	Sell	726 -1,978	-73%	-$49.7K	﹤0.01%	974
2019 Q1	$72K	Buy	+2,704	New	+$99.5K	0.01%	876
2017 Q1	–	Sell	-1,250	Closed	-$59K	–	887
2016 Q4	$59K	Buy	1,250 +469	+60%	+$28.8K	0.01%	771
2016 Q3	$56K	Buy	781 +62	+9%	+$4.41K	0.01%	788
2016 Q2	$46K	Buy	+719	New	+$118K	0.01%	734

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BBVA

Banco Bilbao Vizcaya Argentaria Madrid, Spain $16.1B AUM 40.83% 1-Year Est. Return

RFN

RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wedbush Securities's ZVRA Position: Q1 2020 in Review

Wedbush Securities sold out of Zevra Therapeutics (ZVRA) in Q1 2020, closing a stake of 7,747 shares — an estimated $47K sold.

Wedbush Securities first reported a position in ZVRA in Q2 2016 and held it in 7 quarters. The position peaked at $72K in Q1 2019. 29 funds tracked by Wall St. Rank hold ZVRA as of Q1 2020.

Wedbush Securities reported no remaining Zevra Therapeutics position as of Q1 2020 after selling out during the quarter.
Wedbush Securities sold 7,747 Zevra Therapeutics shares in Q1 2020, an estimated $47K.
Wedbush Securities first reported a position in Zevra Therapeutics in Q2 2016 and held it in 7 quarters.
Wedbush Securities's Zevra Therapeutics position peaked at $72K in Q1 2019.
29 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.